期刊文献+

地西他滨桥接异基因造血干细胞移植治疗骨髓增生异常综合征和急性髓样白血病的临床可行性和疗效研究 被引量:5

Clinical observation of feasibility and efficacy of decitabine bridge therapy followed by allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia
原文传递
导出
摘要 目的:探讨地西他滨(decitabine,DAC)作为骨髓增生异常综合征(myelodysplastic syndrome,MDS)和急性髓样白血病(acute myeloid leukemia,AML)患者行异基因造血干细胞移植(allogeneic hematopoietic stem cell transplantation,allo-HSCT)之前的桥接治疗的可行性和疗效。方法:对7例MDS患者和12例AML患者以DAC作为allo-HSCT之前的桥接治疗。结果:DAC桥接治疗后,7例MDS患者中,4例获得完全缓解(complete remission,CR)/mCR(marrow CR),3例为疾病稳定(stable disease,SD),之后行allo-HSCT成功,目前6例为无病生存,1例在复发后接受供者淋巴细胞输注(donor lymphocyte infusion,DLI)后达CR,后死于肺部感染;12例AML患者中,6例在DAC桥接治疗后获得CR,目前5例为无病生存,6例死亡,1例为带瘤生存。急性和慢性GVHD发生率分别为31.6%和21.1%。DAC桥接治疗后2年总生存率为56.7%,allo-HSCT后2年总生存率和2年累积复发率分别为57.9%和36.2%,allo-HSCT后2年累积非复发死亡率为23.6%。结论:DAC可安全有效地桥接allo-HSCT以治疗MDS和AML患者。 Objective: To investigate the feasibility and efficacy of DAC (decitabine) bridge therapy followed by alIo-HSCT (allogeneic hematopoietic stem cell transplantation) in patients with MDS (myelodysplastic syndrome) and AML (acute myeloid leukemia). Methods: Seven patients with MDS and 1 2 patients with AML received DAC bridge therapy followed by alIo-HSCT. Results: With DAC bridge therapy,4 MDS patients achieved complete remission/marrow complete remission and 3 remained stable disease before alIo-HSCT. After successful engraftment attained in all the seven MDS patients, six survived without disease, one received donor lymphocyte infusion and obtained complete remission after relapse and eventually died of pneumonia. Of 12 AML patients, 6 achieved complete remission after DAC bridge therapy; 5 survived without disease, one still survived but having disease, and 6 had died. The rates of acute and chronic GVHD were 31.6% and 21.1%, respectively. The two-year overall survival rate and the two-year cumulative recurrence rate were 57.9% and 36.2% after alIo-HSCT, respectively. The two-year cumulative recurrence-free rate was 23.6% after alIo-HSCT. Conclusion: DAC regimen can be safely and efficiently administrated to bridge time to alIo-HSCT in patients with MDS/AML.
出处 《肿瘤》 CAS CSCD 北大核心 2013年第3期264-270,共7页 Tumor
基金 国家科技支撑计划资助项目(编号:2008BAI61B02) 卫生公益性行业科研专项经费资助项目(编号:201202017) 江苏省医学重点人才资助项目(编号:H201126) 江苏高校优势学科建设工程一期资助项目 江苏省临床医学中心(高技术平台)建设资助项目(编号:ZX201102) 江苏省高校自然科学研究项目(编号:09KJB320015)
关键词 骨髓增生异常综合征 白血病 髓样 急性 地西他滨 造血干细胞移植 桥接治疗 Myelodysplastic symdroms Leukemia, myeloid, acute Decitabine Hematopoietic stem cell transplantation Bridge therapy
  • 相关文献

参考文献18

  • 1急性髓系白血病(复发难治性)中国诊疗指南(2011年版)[J].中华血液学杂志,2011,32(12):887-888. 被引量:90
  • 2CHESON B D, GREENBERG P L, BENNETTJ M, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia[j]o Blood, 2006, 108(2):419-425. 被引量:1
  • 3KANTARJIAN H, ISSA J P, ROSENFELD C S, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study[J]. Cancer, 2006, 106(8):1794-1803. 被引量:1
  • 4KANTARJIAN H, OKI Y, GARCIA-MANERO G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in leukemia higher- risk myelodysplastic syndrome and chronic myelomonocytic leukemia[J]. Blood, 2007, 109(1):52-57. 被引量:1
  • 5LUBBERT M, SUCIU S, BAILA L, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase IlI study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group[J].J C/in Oncol, 2011, 29(15):1987-1996. 被引量:1
  • 6WANG H, WANG X Q, XU X P, et al. ID4 methylation predicts high risk of leukemic transformation in patients with myelodysplastic syndrome[J]. Leukemia Res, 201 0, 34(5):598-604. 被引量:1
  • 7BENETATOS L, HATZIMICHAEL E, DASOUL A, et al. CpG methylation analysis of the MEG3 and SNRPN imprinted genes in acute myeloid leukemia and myelodysplastic syndromes[J]. Leukemia Res, 2010, 34(2):148-153. 被引量:1
  • 8邵宗鸿,张薇.骨髓增生异常综合征去甲基化治疗进展[J].临床血液学杂志,2011,24(3):259-261. 被引量:11
  • 9MORI N, YOSHINAGA K, TOMITA K, et al. Aberrant methylation of the RIZ1 gene in myelodysplastic syndrome and acute myeloid leukemia[J]. Leukemia Res, 2011 35(4):51 6 - 521. 被引量:1
  • 10THOMAS X G, DMOSZYNSKA A, WlERZBOWSKA A, et al. Results from a randomized phase III trial of decitabine versus supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed AML[J].J C/in Oncol, 2011, 29(Suppl):Abstract 6504. 被引量:1

二级参考文献24

  • 1NIMER S D. Myelodysplastic syndromes[J]. Blood, 2008, 111:4841-4851. 被引量:1
  • 2NOLTE F, HOFMANN W K, Molecular mechanisms in- volved in the progression of myelodysplastie syndrome[J]. Future Oncol, 2010, 6:445- 455. 被引量:1
  • 3BACHER U, HAFERLACH T, KERN W, et al. A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia[J]. Haematologica, 2007, 92:744 - 752. 被引量:1
  • 4MIHARA K, TAKIHARA Y, KIMURA A. Genetic and epigenetic alterations in myelodysplastic syndrome[J]. Cy- togenet Genome Res, 2007, 118 : 297- 303. 被引量:1
  • 5BRAKENSIEK K, LANGER F, SCHLEGELBERGER B, et al. Hypermethylation of the suppressor of eytokine sig- nalling-1(SOCS-1) in myelodysplastic syndrome[J]. Br J Haematol, 2005,130:209-217. 被引量:1
  • 6LIN J, YAO D M, QIAN J, et al. Methylation status of fragile histidine triad(FHIT) gene and its clinical impact on prognosis of patients with myelodysplastic syndrome[J]. Leuk Res, 2008, 32:1541- 1545. 被引量:1
  • 7ACaSERHOLM A, HOLM M S, GULDBERG P, et al. Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and pre dicts poor prognosis in early-stage patients [J]. Eur J Haematol, 2006, 76: 23-32. 被引量:1
  • 8SHEN L, KANTARJIAN H, GUO Y, et al. DNA meth- ylation predicts survival and response to therapy in patients with myelodysplastic syndromes[J]. J Clin Oncol, 2010, 28:605-613. 被引量:1
  • 9TEENSMA D P, STONE R M. Practical recommenda- tions for hypomethylating agent therapy of patients with myelodysplastic syndromes[J]. Hematol Oncol Clin North Am, 2010,24 : 389- 406. 被引量:1
  • 10LEONE G, DM.O F, ZARDO G, et al. Epigenetic treat- ment of myelodysplastic syndromes and acute myeloid leu kemias[J]. Curr Med Chem. 2008,15:1274 -1287. 被引量:1

共引文献98

同被引文献82

  • 1蔡成森,孙爱宁,仇惠英,何广胜,唐晓文,金正明,傅琤琤,吴德沛.地西他滨单药及联合AAG方案治疗初治急性髓系白血病的临床观察[J].中华临床医师杂志(电子版),2012,6(19):6092-6094. 被引量:13
  • 2徐泽锋,肖志坚.地汐他滨治疗骨髓增生异常综合征的研究进展[J].中华血液学杂志,2007,28(1):61-64. 被引量:4
  • 3Greenberg P. The myelodysplastic syndromes [M]. Hoffman R, Benz E, Shattil S, et al. Hematology: Basic Principles and Practice. 3 th ed. New York: Churchill Livingstone, 2000:1106- 1129. 被引量:1
  • 4Witherspoon RP, Deeg HJ. Allogeneic bone marrow transplanta- tion for secondary leukemia or myelodysplasia [J] Haematologica, 1999, 84( 12): 1085-1087. 被引量:1
  • 5Platzbecker U, Mufti G. Allogeneic stem cell transplantation in mds: how when[J]. Best Pract Res Clin Haematol, 2013, 26(4): 421-429. 被引量:1
  • 6Soriano AO, Yang H, Faderl S, et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome[J]. Blood, 2007, 110(7): 2302-2308. 被引量:1
  • 7Greenberg PL, Attar E, Bennett JM, et al. NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes [ J ]. J Natl Compr Canc Netw, 2011, 9 ( 1 ) :30-56. 被引量:1
  • 8Engel N, Rank A. Epigenomics in hematopoietic transplantation: novel treatment strategies [J]. Epigenomics, 2011, 3 (5): 611- 623. 被引量:1
  • 9O' Donnell MR, Appelbaum FR, Baer MR, et al. Acute myeloid leukemia clinical practice guidelines in oncology IJ]. J Natl Compr Canc Netw, 2006, 4( 1 ):16-36. 被引量:1
  • 10Mahmud M, Stebbing J. Epigenetic modifications in AML and MDS[J]. Leuk Res, 2010, 34(2): 139-140. 被引量:1

引证文献5

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部